3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
NETWORK
2
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Colorectal Neoplasms
62
Carcinoma, Hepatocellular
25
Neoplasm Metastasis
15
Rectal Neoplasms
11
Colonic Neoplasms
10
Gastrointestinal Stromal Tumors
9
Sarcoma
6
Ovarian Neoplasms
5
Osteosarcoma
5
Glioblastoma
5
Cholangiocarcinoma
5
Stomach Neoplasms
4
Melanoma
4
Liver Neoplasms
4
Sarcoma, Ewing
3
Pancreatic Neoplasms
3
Neoplasms
3
Leukemia, Myeloid, Acute
3
Esophageal Neoplasms
3
Colorectal Cancer Metastatic
3
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Rhabdomyosarcoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
Hemangiosarcoma
2
Gastrointestinal Neoplasms
2
Interventions
Oxaliplatin
32
Fluorouracil
24
Gemcitabine
23
Leucovorin
19
Docetaxel
19
pembrolizumab
17
Capecitabine
15
Radiotherapy
14
Irinotecan
13
Cisplatin
11
Bevacizumab
11
Nivolumab
8
130-nm albumin-bound paclitaxel
8
Trastuzumab
7
Erlotinib Hydrochloride
7
Cyclophosphamide
7
Albumin-Bound Paclitaxel
7
Radiosurgery
6
Paclitaxel
6
Taxes
5
S 1 (combination)
5
Metformin
5
Carboplatin
5
Blood Specimen Collection
5
Sunitinib
4
Sorafenib
4
Pemetrexed
4
Esophagectomy
4
Chemoradiotherapy
4
Cetuximab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma
×
regorafenib
×
Clear all
NCT03722108
2023-10-16
REGIRI
UNICANCER
Phase 1/2
Terminated
89 enrolled
NCT01929616
2019-06-25
RegARd-C
Jules Bordet Institute
Phase 2
Completed
141 enrolled